Durvalumab and Tremelimumab: Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi^®; Tremelimumab: Solution concentrate for I.V. infusion 300 mg in 15 mL; Imjudo^®

Page last updated: 29 August 2025

• Public Summary Document (PSD) May 2025 PBAC Meeting – (PDF 856KB)
• Public Summary Document (PSD) May 2025 PBAC Meeting – (Word 344KB)